Carcinosarcoma of the Ovary: A Case Report
Clinical Medicine Research
Volume 3, Issue 4, July 2014, Pages: 90-93
Received: Apr. 15, 2014; Accepted: Jul. 5, 2014; Published: Jul. 20, 2014
Views 2763      Downloads 157
Authors
Abdellah Babahabib, Department of Gynecology-obstetrics, Military Training Hospital Med V, Rabat, Morocco
Mohamed Elmarjany, Department of Radiotherapy, Military Training Hospital Med V, Rabat, Morocco
Hicham Bakkali, Department of Anesthesiology and Critical Care, Military Training Hospital Med V, Rabat, Morocco
Mehdi Elhassani, Department of Gynecology-obstetrics, Military Training Hospital Med V, Rabat, Morocco
Jaouad Kouach, Department of Gynecology-obstetrics, Military Training Hospital Med V, Rabat, Morocco
Rhali Driss Moussaoui, Department of Gynecology-obstetrics, Military Training Hospital Med V, Rabat, Morocco
Mohamed Dehayni, Department of Gynecology-obstetrics, Military Training Hospital Med V, Rabat, Morocco
Article Tools
Follow on us
Abstract
The carcinosarcoma is a mixed tumour composed of epithelial and mesenchymatous malignant tissus. It can occur on the level of all the female genital tract, most frequently the uterus. The ovarian localization is rare. The purpose of our work is to discuss the problems of differential diagnosis raised by this rare entity. We report the case of a 60 years old patient, who consulted for an abdominal mass of 20 cm. Tomodensitometry of the abdomen and the pelvic had objectified the right ovarian origin. The patient was treated by total colpohysterectomy with bilateral annexectomy. Through this case with review of the literature we shall discuss the histogenetic assumptions of this entity which are the object of controversies as well as the prognosis and therapeutic implications.
Keywords
Carcinosarcoma, Malignant Mixed Mesodermal Tumor, Ovarian Cancer, Chemotherapy
To cite this article
Abdellah Babahabib, Mohamed Elmarjany, Hicham Bakkali, Mehdi Elhassani, Jaouad Kouach, Rhali Driss Moussaoui, Mohamed Dehayni, Carcinosarcoma of the Ovary: A Case Report, Clinical Medicine Research. Vol. 3, No. 4, 2014, pp. 90-93. doi: 10.11648/j.cmr.20140304.12
References
[1]
Silasi DA, Illuzzi JL, Kelly MG , Rutherford TJ, Mor G, Azodi M, Schwartz PE.. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008; 18: 22-29.
[2]
Navirini R, Pineda RL. Malignant mixed mullerian tumors of the ovary. curr opin obstet gyneco 2006; 18:20-23.
[3]
Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM 2nd, Schorge JO, Horowitz NS, del Carmen MG.. Carcinosarcoma of the ovary: a case-control study. Gynecologic.Oncology,2011; 121: 477-481.
[4]
Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, Shanks JH, Wilson G, Slade RJ, Reynolds K, Jayson GC. Carcinosarcoma of the ovary. Br J Cancer 2003; 88: 654-57.
[5]
Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH. Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer 2006; 16: 101-105.
[6]
Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, Motoyama T. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003; 22:368-73.
[7]
Wei LH, Huang CY, Cheng SP, Chen CA, Hsieh CY. Carcinosarcoma of ovary associated with previous radiotherapy. Int J Gynecol Cancer 2001; 11: 81-84.
[8]
Tate TJ, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas : a Gynecologic Oncology Group Study. Gynecol Oncol 2004; 93: 336-39.
[9]
Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E. Ovarian carcinosarcomas: clinocopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008; 108: 136-40.
[10]
Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, Mutch DG, Johnson GA, Walker JL, Mannel RS. Carcinosarcoma of the ovary - a case series. Gynecol Oncol 2006; 100: 128-32.
[11]
Paulsson G, Andersson S, Sorbe B. A population-based series of ovarian carcinosarcomas with long-term follow-up. Anticancer Research, 2013; 3: 1003–1008.
[12]
Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, Smyth J, Gabra H. Carcinosarcoma of the ovary: 19years of prospective data from a single center. Cancer 2004;100: 2148–53.
[13]
Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD; GynecologicOncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 2004;93:336–9.
[14]
Chun KC, Kim JJ, Kim DY et al. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience. Gynecologic and Obstetric Investigation 2011; 72: 208–214,
[15]
Zorzou MP, Markaki S, Rodolakis S et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol 2005;96:136–42
[16]
Crotzer DR, Wolf JK, Jenkins AD, Gershenson DM, Levenback C. Apilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Proc Am Soc Clin Oncol 2003;22:474.
[17]
Rutledge TL, Gold MA, McMeekin DS et al. Carcinosarcoma of the ovary—a case series. Gynecol Oncol 2006;100:128–32.
[18]
Signorelli M, Chiappa V, Minig L, Fruscio R, Perego P, Caspani G, Battistello M, Colombo N.Platinum, anthracycline,and alkylating agent-based chemotherapy for ovarian carcinosarcoma. International Journal of Gynecological Cancer 2009; 19: 1142–1146.
[19]
Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH.. Malignant mixed mullerian tumors of the ovary: experience with cytoreductive surgery and platinumbased combination chemotherapy. Int J Gynecol Cancer 2006;16 :101–5.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186